Skip to main content
Premium Trial:

Request an Annual Quote

Roche Signs AgenoLab as First Customer for xCelligence Cell Analysis System

NEW YORK (GenomeWeb News) – Roche Applied Science said today that biotech services company AgenoLab has installed the xCelligence System, which Roche distributes through a partnership with Acea Biosciences.
 
Roche said Stuttgart, Germany-based AgenoLab purchased the xCelligence in April and installed it in July, making it the first customer to purchase the cell-based assay platform.
 
AgenoLab performs services in microbiology, molecular biology, cell culture technology, tissue engineering, and in other biomedical areas.
 
The system was originally developed by the San Diego-based Acea and was further developed with Roche as part of a marketing agreement the companies signed in November 2007.
 
Roche holds exclusive worldwide marketing rights to the technology.
 
The xCelligence platform is a label-free system that monitors cellular events in real time. It uses electrical impedance measurement to provide information about cell number, viability, and morphology.
 
Financial terms of the agreement with AgenoLab were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.